Dinutuximab is a monoclonal antibody that targets a substance found on certain cells. In this case, it targets the glycolipid GD2. Dinutuximab binds specifically to GD2, which is expressed on the surface of neuroblastoma tumor cells, as well as some normal cells. Dinutuximab binds to GD2 and causes cells to break down and die.